Pulmozyme, generically known as dornase alfa, is a medication primarily used in the management of cystic fibrosis. It works by breaking down DNA in the thick mucus secretions in the lungs, which are a hallmark of this condition, thereby helping to improve lung function and reduce the risk of infections. Pulmozyme is administered through inhalation, allowing direct delivery to the lungs. This medication is often part of a broader treatment regimen for individuals with cystic fibrosis, aimed at managing symptoms and improving quality of life. It is important for patients to follow their healthcare provider's instructions closely when using Pulmozyme to ensure its effectiveness and to monitor for any potential side effects.